Role of Autologous Micrografting Technology through Rigenera® System in the Treatment of Androgenetic Alopecia

Le résumé fourni par la source

Introduction: Androgenetic alopecia (AGA) is a common form of baldness, affecting 60–70% of the adult population worldwide, and may have a negative effect on quality life. AGA leads to a progressive thinning of scalp hair and is characterized by a progressive miniaturization of the hair follicle with a specific pattern distribution. Although AGA is a very frequent condition, compelling therapeutic options are still limited. Methods: Herein, we present the protocol of autologous micrografting technology through Rigenera® system allowing to obtain a suspension of autologous micrografts ready to be injected on scalp. This paper combines the results of two studies that evaluated the effects of micrografts in patients with AGA. The first study involved 17 patients who received one micrografts session with a 6-month follow-up. The second study 13 patients who received two micrografts sessions 6 months apart with a follow-up of 6 months after the second session. Clinical assessment involved global photography evaluation and patient’s satisfaction before and after the treatment. Hair measures using TrichoLab were also performed. Results: Most of the patients had a moderate improvement after investigator’s assessment in terms of hair loss reduction and hair density improvement. The assessment of patients was satisfactory in terms of hair improvement and treatment tolerability. Conclusion: In summary, we conclude that this new regenerative approach can be a promising tool for clinicians to obtain a viable, sterile and ready to use micrografts that can be immediately injected into the scalp to improve AGA condition.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.